Abstract
Objective: Genome-wide association studies (GWASs) for epithelial ovarian cancer (EOC) have focused largely on populations of European ancestry. We aimed to identify common germline variants associated with EOC risk in Asian women. Methods: Genotyping was performed as part of the OncoArray project. Samples with >60% Asian ancestry were included in the analysis. Genotyping was performed on 533,631 SNPs in 3238 Asian subjects diagnosed with invasive or borderline EOC and 4083 unaffected controls. After imputation, genotypes were available for 11,595,112 SNPs to identify associations. Results: At chromosome 6p25.2, SNP rs7748275 was associated with risk of serous EOC (odds ratio [OR] = 1.34, P = 8.7 × 10 −9 ) and high-grade serous EOC (HGSOC) (OR = 1.34, P = 4.3 × 10 −9 ). SNP rs6902488 at 6p25.2 (r 2 = 0.97 with rs7748275) lies in an active enhancer and is predicted to impact binding of STAT3, P300 and ELF1. We identified additional risk loci with low Bayesian false discovery probability (BFDP) scores, indicating they are likely to be true risk associations (BFDP <10%). At chromosome 20q11.22, rs74272064 was associated with HGSOC risk (OR = 1.27, P = 9.0 × 10 −8 ). Overall EOC risk was associated with rs10260419 at chromosome 7p21.3 (OR = 1.33, P = 1.2 × 10 −7 ) and rs74917072 at chromosome 2q37.3 (OR = 1.25, P = 4.7 × 10 −7 ). At 2q37.3, expression quantitative trait locus analysis in 404 HGSOC tissues identified ESPNL as a putative candidate susceptibility gene (P = 1.2 × 10 −7 ). Conclusion: While some risk loci were shared between East Asian and European populations, others were population-specific, indicating that the landscape of EOC risk in Asian women has both shared and unique features compared to women of European ancestry.
Original language | English |
---|---|
Pages (from-to) | 343-355 |
Number of pages | 13 |
Journal | Gynecologic Oncology |
Volume | 153 |
Issue number | 2 |
DOIs | |
State | Published - May 2019 |
Keywords
- Asian ancestry
- Enhancer
- Epithelial ovarian cancer
- Gene regulation
- Genome-wide association study
- eQTL
Access to Document
Fingerprint
Dive into the research topics of 'Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Gynecologic Oncology, Vol. 153, No. 2, 05.2019, p. 343-355.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women
AU - The Australian Ovarian Cancer Study Group
AU - Lawrenson, Kate
AU - Song, Fengju
AU - Hazelett, Dennis J.
AU - Kar, Siddhartha P.
AU - Tyrer, Jonathan
AU - Phelan, Catherine M.
AU - Corona, Rosario I.
AU - Rodríguez-Malavé, Norma I.
AU - Seo, Ji Hei
AU - Adler, Emily
AU - Coetzee, Simon G.
AU - Segato, Felipe
AU - Fonseca, Marcos A.S.
AU - Amos, Christopher I.
AU - Carney, Michael E.
AU - Chenevix-Trench, Georgia
AU - Choi, Jiyeob
AU - Doherty, Jennifer A.
AU - Jia, Weihua
AU - Jin, Gang J.
AU - Kim, Byoung Gie
AU - Le, Nhu D.
AU - Lee, Juyeon
AU - Li, Lian
AU - Lim, Boon K.
AU - Adenan, Noor A.
AU - Mizuno, Mika
AU - Park, Boyoung
AU - Pearce, Celeste L.
AU - Shan, Kang
AU - Shi, Yongyong
AU - Shu, Xiao Ou
AU - Sieh, Weiva
AU - Thompson, Pamela J.
AU - Wilkens, Lynne R.
AU - Wei, Qingyi
AU - Woo, Yin L.
AU - Yan, Li
AU - Karlan, Beth Y.
AU - Freedman, Matthew L.
AU - Noushmehr, Houtan
AU - Goode, Ellen L.
AU - Berchuck, Andrew
AU - Sellers, Thomas A.
AU - Teo, Soo Hwang
AU - Zheng, Wei
AU - Matsuo, Keitaro
AU - Park, Sue
AU - Chen, Kexin
AU - Pharoah, Paul D.P.
N1 - Funding Information: National Health & Medical Research Council (NHMRC) of Australia 199600 and 400281 (AUS, AOCS), 209057, 251533, 396414 and 504715 (MCC), RBH, APP1025142 (OPL) and 310670 and 628903 (WMH); Cancer Councils of New South Wales, Victoria, Queensland, South Australia and Tasmania, and Cancer Foundation of Western Australia under Multi-State Application Numbers 191, 211 and 182 (AUS/AOCS); Cancer Council Victoria (MCC); Brisbane Women's Club (OPL); Cancer Institute NSW 11/TRC/1-06 and 12/RIG/1-17 (WMH). GCT & PW are supported by Fellowships from NHMRC. KAP is an Australian National Breast Cancer Foundation Practitioner Fellow. Funding Information: A study acronym JPN was supported in part by Grants-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science and Technology , consisting of Priority Areas of Cancer (No. 17015018 ), Innovative Areas (No. 221S0001 ), JSPS KAKENHI Grant (No. 16H06277 and 26253041 ) and Grant-in-Aid for the Third Term Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health, Labour and Welfare . The authors thank study participants and research staff of the Shanghai Women's Health Study (SWHS) for their contributions and commitment to this project. The SWHS is supported in part by National Cancer Institute grants (U.S.A) UM1 CA182910 . Funding Information: The OCAC OncoArray genotyping project was funded through grants from the U.S. National Institutes of Health (NIH) ( CA1X01HG007491-01 , U19-CA148112 , R01-CA149429 and R01-CA058598 ); Canadian Institutes of Health Research ( MOP-86727 ) and the Ovarian Cancer Research Fund (OCRF). Funding Information: Genotyping of the iCOGS array was funded by the European Union [ HEALTH-F2-2009-223175 ], Cancer Research UK [ C1287/A10710 , C1287/A10118 , C12292/A11174 ], NIH grants ( R01 CA114343 , R01 CA149429 , R01 CA176016 , R01 CA128978 , R01 CA116167 , R01 CA176785 and R01-CA058598 ), the GAME-ON initiative ( 1U19 CA148537 , 1U19 CA148065 and 1U19 CA148112 ), an NCI Specialized Program of Research Excellence (SPORE) in Breast Cancer ( P50 CA116201 ), the Canadian Institutes of Health Research (CIHR) ( MOP-86727 ), the CIHR Team in Familial Risks of Breast Cancer , the Ministère de l'Économie, Innovation et Exportation du Québec (# PSR-SIIRI-701 ), Komen Foundation for the Cure , the Breast Cancer Research Foundation (BCRF), the OCRF and National Health and Medical Research Council of Australia grant # 1017028 . Funding Information: The OCAC OncoArray genotyping project was funded through grants from the U.S. National Institutes of Health (NIH) (CA1X01HG007491-01, U19-CA148112, R01-CA149429 and R01-CA058598); Canadian Institutes of Health Research (MOP-86727) and the Ovarian Cancer Research Fund (OCRF).Genotyping of the iCOGS array was funded by the European Union [HEALTH-F2-2009-223175], Cancer Research UK [C1287/A10710, C1287/A10118, C12292/A11174], NIH grants (R01 CA114343, R01 CA149429, R01 CA176016, R01 CA128978, R01 CA116167, R01 CA176785 and R01-CA058598), the GAME-ON initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112), an NCI Specialized Program of Research Excellence (SPORE) in Breast Cancer (P50 CA116201), the Canadian Institutes of Health Research (CIHR) (MOP-86727), the CIHR Team in Familial Risks of Breast Cancer, the Ministère de l'Économie, Innovation et Exportation du Québec (#PSR-SIIRI-701), Komen Foundation for the Cure, the Breast Cancer Research Foundation (BCRF), the OCRF and National Health and Medical Research Council of Australia grant #1017028.Funding for the US GWAS and Mayo GWAS was provided by NIH R01 CA114343 and U19-CA148112. The UK GWAS genotyping and data analysis were supported by Cancer Research UK (C490/A8339) and the Wellcome Trust (076113). The expression Quantitative Trait Locus analyses results published here are in part also based upon data generated by The Cancer Genome Atlas (TCGA) Research Network. This work was also supported by the National Natural Science Foundation of China (81320108022, 81502877), the Program for Changjiang Scholars and Innovative Research Team in University (PCSIRT) in China (IRT_14R40), Tianjin Science and Technology Committee Foundation (16JCYBJC26600), National Human Genetic Resources Sharing Service Platform (2005DKA21300), The National Key Research and Development program of China: The Net construction of human genetic resource Bio-bank in North China (2016YFC1201703).The OCAC database management is supported by a grant from the OCRF thanks to donations by the family and friends of Kathryn Sladek Smith (PPD/RPCI.07).Funding for individual studies are provided by ULTR000445 (BVU); R01-CA112523, R01-CA087538, (DOV); R01-CA058598, N01-CN-55424, N01-PC-67001 (HAW); K07-CA080668, R01-CA095023, P50-CA159981, NIH/National Center for Research Resources/General Clinical Research Center grant MO1-RR000056 (HOP); National Center for Advancing Translational Sciences (NCATS) UL1TR000124 (LAX); R01-CA122443, P30-CA15083, P50-CA136393 (MAC/MAY); R01-CA054281, R01-CA164973, R01-CA063464 (MEC); R01-CA114343 (MOF); R01-CA076016 (NCO); R01-CA054419, P50-CA105009 (NEC); R01-CA067262, UM1 CA176726, UM1 CA186107, P01 CA087969, R01 CA049449 (NHS); R01CA160669 (OVA); P50 CA159981, R01CA126841 (RPC); National Institute of Environmental Health Sciences (NIEHS) (Z01 ES044005) (SIS); U01-CA071966, R01-CA016056, U01-CA069417 (STA); R01 CA063678, R01 CA063682 (TOR); R01-CA058860 (UCI); P01CA17054, P30CA014089, R01CA061132, N01PC67010, R03CA113148, R03CA115195, N01CN025403 (USC).A study acronym JPN was supported in part by Grants-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science and Technology, consisting of Priority Areas of Cancer (No. 17015018), Innovative Areas (No. 221S0001), JSPS KAKENHI Grant (No. 16H06277 and 26253041) and Grant-in-Aid for the Third Term Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health, Labour and Welfare. The authors thank study participants and research staff of the Shanghai Women's Health Study (SWHS) for their contributions and commitment to this project. The SWHS is supported in part by National Cancer Institute grants (U.S.A) UM1 CA182910.U.S. Department of Defense (DoD) Congressionally Directed Medical Research Program (CDMRP): DAMD17-01-1-0729 (AUS); DAMD17-02-1-0669 (HOP); W81XWH-07-0449 (MDA); DAMD17-02-1-0666 (NCO); W81XWH-10-1-02802 (NEC).American Cancer Society (ACS) Early Detection Professorship (SIOP-06-258-01-COUN) (LAX); ACS (CRTG-00-196-01-CCE); Ovarian Cancer Research Fund (OCRF) (DKE); Roswell Park Cancer Institute Alliance Foundation (RPC); Mayo Foundation; Minnesota Ovarian Cancer Alliance; Fred C. and Katherine B. Andersen Foundation; Fraternal Order of Eagles (MAC/MAY); OHSU Foundation (ORE); Intramural Research Program of the National Cancer Institute (SIS); Lon V Smith Foundation grant LVS-39420 (UCI); California Cancer Research Program (00-01389 V-20170, 2II0200) (USC). KL is funded by a K99/R00 Pathway to Independence Award from the NCI (R00CA184415). Additional support came from Sao Paulo Research Foundation (FAPESP) grants: 2015/07925-5, 2017/08211-1 (MASF, FS, HN) and institutional grants from Henry Ford Hospital (HN). Funding Information: The Australian Ovarian Cancer Study (AOCS) Management Group (D. Bowtell, A. deFazio, D. Gertig, A. Green, P. Webb); ACS Investigators (A. Green, P. Parsons, N. Hayward, P. Webb, D. Whiteman) and collaborators (see http://www.aocstudy.org ) (ACS). Gilian Peuteman, Thomas Van Brussel, Annick Van den Broeck and Joke De Roover for technical assistance (BEL); The dataset(s) used for the analyses described for BioVU were obtained from Vanderbilt University Medical Center's BioVU which is supported by institutional funding, the 1S10RR025141-01 instrumentation award, and by the Vanderbilt CTSA grant UL1TR000445 from NCATS/NIH. (BVU); CRUK; the University of Cambridge; NIHR Cambridge Biomedical Research Centre (CAM); the Australian Cancer Database (MCC); The Total Cancer Care™ Protocol and the Collaborative Data Services and Tissue Core Facilities at the H. Lee Moffitt Cancer Center & Research Institute, an NCI designated Comprehensive Cancer Center (P30-CA076292), Merck Pharmaceuticals and the state of Florida (MOF). The following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, and WY (NHS). Caroline Baynes and Don Conroy (SEA); I. Jacobs, M. Widschwendter, E. Wozniak, A. Ryan, J. Ford and N. Balogun (UKO); Gynecological Oncology Biobank at Westmead, a member of the Australasian Biospecimen Network-Oncology group (WMH). Funding Information: Funding for individual studies are provided by ULTR000445 ( BVU ); R01-CA112523 , R01-CA087538 , ( DOV ); R01-CA058598 , N01-CN-55424 , N01-PC-67001 ( HAW ); K07-CA080668 , R01-CA095023 , P50-CA159981 , NIH / National Center for Research Resources / General Clinical Research Center grant MO1-RR000056 (HOP); National Center for Advancing Translational Sciences (NCATS) UL1TR000124 (LAX); R01-CA122443 , P30-CA15083 , P50-CA136393 ( MAC/MAY ); R01-CA054281 , R01-CA164973 , R01-CA063464 ( MEC ); R01-CA114343 ( MOF ); R01-CA076016 ( NCO ); R01-CA054419 , P50-CA105009 ( NEC ); R01-CA067262 , UM1 CA176726 , UM1 CA186107 , P01 CA087969 , R01 CA049449 ( NHS ); R01CA160669 ( OVA ); P50 CA159981 , R01CA126841 ( RPC ); National Institute of Environmental Health Sciences (NIEHS) ( Z01 ES044005 ) (SIS); U01-CA071966 , R01-CA016056 , U01-CA069417 ( STA ); R01 CA063678 , R01 CA063682 ( TOR ); R01-CA058860 ( UCI ); P01CA17054 , P30CA014089 , R01CA061132 , N01PC67010 , R03CA113148 , R03CA115195 , N01CN025403 ( USC ). Funding Information: ELAN Funds of the University of Erlangen-Nuremberg (BAV); Nationaal Kankerplan (BEL); Instituto de Salud Carlos III (PI 12/01319); Ministerio de Economía y Competitividad (SAF2012-35779) (CNI); German Federal Ministry of Education and Research, Programme of Clinical Biomedical Research (01 GB 9401) and the German Cancer Research Center (DKFZ) (GER); European Union (European Social Fund - ESF) and Greek national funds through the Operational Program “Education and Lifelong Learning” of the National Strategic Reference Framework (NSRF) - Research Funding Program of the General Secretariat for Research & Technology: SYN11_10_19 NBCA (GRC); Helsinki University Research Fund (HOC); Rudolf-Bartling Foundation (HMO and HUO); Radboud University Medical Centre (NTH); Herlev Hospitals Forskningsråd, Direktør Jacob Madsens og Hustru Olga Madsens fond, Arvid Nilssons fond, Gangsted fonden, Herlev Hospitals Forskningsråd and Danish Cancer Society (PVD). Funding Information: The coordination of EPIC (EPC) is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer (IARC). The national cohorts are supported by Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l'Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF) (Germany); the Hellenic Health Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); ERC-2009-AdG 232997 and Nordforsk, Nordic Centre of Excellence Programme on Food, Nutrition and Health (Norway); Health Research Fund (FIS), PI13/00061 to Granada, PI13/01162 to EPIC-Murcia, Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, ISCIII RETIC (RD06/0020) (Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden); CRUK (14136 to EPIC-Norfolk; C570/A16491 and C8221/A19170 to EPIC-Oxford), Medical Research Council (MRC) (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (United Kingdom). Funding Information: Funding for the US GWAS and Mayo GWAS was provided by NIH R01 CA114343 and U19-CA148112 . The UK GWAS genotyping and data analysis were supported by Cancer Research UK ( C490/A8339 ) and the Wellcome Trust ( 076113 ). The expression Quantitative Trait Locus analyses results published here are in part also based upon data generated by The Cancer Genome Atlas (TCGA) Research Network. This work was also supported by the National Natural Science Foundation of China ( 81320108022 , 81502877 ), the Program for Changjiang Scholars and Innovative Research Team in University (PCSIRT) in China ( IRT_14R40 ), Tianjin Science and Technology Committee Foundation ( 16JCYBJC26600 ), National Human Genetic Resources Sharing Service Platform ( 2005DKA21300 ), The National Key Research and Development program of China : The Net construction of human genetic resource Bio-bank in North China ( 2016YFC1201703 ). Funding Information: The OCAC database management is supported by a grant from the OCRF thanks to donations by the family and friends of Kathryn Sladek Smith ( PPD/RPCI.07 ). Funding Information: American Cancer Society (ACS) Early Detection Professorship (SIOP-06-258-01-COUN) (LAX); ACS (CRTG-00-196-01-CCE); Ovarian Cancer Research Fund (OCRF) (DKE); Roswell Park Cancer Institute Alliance Foundation (RPC); Mayo Foundation; Minnesota Ovarian Cancer Alliance; Fred C. and Katherine B. Andersen Foundation; Fraternal Order of Eagles (MAC/MAY); OHSU Foundation (ORE); Intramural Research Program of the National Cancer Institute (SIS); Lon V Smith Foundation grant LVS-39420 (UCI); California Cancer Research Program (00-01389 V-20170, 2II0200) (USC). KL is funded by a K99/R00 Pathway to Independence Award from the NCI (R00CA184415). Additional support came from Sao Paulo Research Foundation ( FAPESP ) grants: 2015/07925-5 , 2017/08211-1 (MASF, FS, HN) and institutional grants from Henry Ford Hospital (HN). Publisher Copyright: © 2019
PY - 2019/5
Y1 - 2019/5
N2 - Objective: Genome-wide association studies (GWASs) for epithelial ovarian cancer (EOC) have focused largely on populations of European ancestry. We aimed to identify common germline variants associated with EOC risk in Asian women. Methods: Genotyping was performed as part of the OncoArray project. Samples with >60% Asian ancestry were included in the analysis. Genotyping was performed on 533,631 SNPs in 3238 Asian subjects diagnosed with invasive or borderline EOC and 4083 unaffected controls. After imputation, genotypes were available for 11,595,112 SNPs to identify associations. Results: At chromosome 6p25.2, SNP rs7748275 was associated with risk of serous EOC (odds ratio [OR] = 1.34, P = 8.7 × 10 −9 ) and high-grade serous EOC (HGSOC) (OR = 1.34, P = 4.3 × 10 −9 ). SNP rs6902488 at 6p25.2 (r 2 = 0.97 with rs7748275) lies in an active enhancer and is predicted to impact binding of STAT3, P300 and ELF1. We identified additional risk loci with low Bayesian false discovery probability (BFDP) scores, indicating they are likely to be true risk associations (BFDP <10%). At chromosome 20q11.22, rs74272064 was associated with HGSOC risk (OR = 1.27, P = 9.0 × 10 −8 ). Overall EOC risk was associated with rs10260419 at chromosome 7p21.3 (OR = 1.33, P = 1.2 × 10 −7 ) and rs74917072 at chromosome 2q37.3 (OR = 1.25, P = 4.7 × 10 −7 ). At 2q37.3, expression quantitative trait locus analysis in 404 HGSOC tissues identified ESPNL as a putative candidate susceptibility gene (P = 1.2 × 10 −7 ). Conclusion: While some risk loci were shared between East Asian and European populations, others were population-specific, indicating that the landscape of EOC risk in Asian women has both shared and unique features compared to women of European ancestry.
AB - Objective: Genome-wide association studies (GWASs) for epithelial ovarian cancer (EOC) have focused largely on populations of European ancestry. We aimed to identify common germline variants associated with EOC risk in Asian women. Methods: Genotyping was performed as part of the OncoArray project. Samples with >60% Asian ancestry were included in the analysis. Genotyping was performed on 533,631 SNPs in 3238 Asian subjects diagnosed with invasive or borderline EOC and 4083 unaffected controls. After imputation, genotypes were available for 11,595,112 SNPs to identify associations. Results: At chromosome 6p25.2, SNP rs7748275 was associated with risk of serous EOC (odds ratio [OR] = 1.34, P = 8.7 × 10 −9 ) and high-grade serous EOC (HGSOC) (OR = 1.34, P = 4.3 × 10 −9 ). SNP rs6902488 at 6p25.2 (r 2 = 0.97 with rs7748275) lies in an active enhancer and is predicted to impact binding of STAT3, P300 and ELF1. We identified additional risk loci with low Bayesian false discovery probability (BFDP) scores, indicating they are likely to be true risk associations (BFDP <10%). At chromosome 20q11.22, rs74272064 was associated with HGSOC risk (OR = 1.27, P = 9.0 × 10 −8 ). Overall EOC risk was associated with rs10260419 at chromosome 7p21.3 (OR = 1.33, P = 1.2 × 10 −7 ) and rs74917072 at chromosome 2q37.3 (OR = 1.25, P = 4.7 × 10 −7 ). At 2q37.3, expression quantitative trait locus analysis in 404 HGSOC tissues identified ESPNL as a putative candidate susceptibility gene (P = 1.2 × 10 −7 ). Conclusion: While some risk loci were shared between East Asian and European populations, others were population-specific, indicating that the landscape of EOC risk in Asian women has both shared and unique features compared to women of European ancestry.
KW - Asian ancestry
KW - Enhancer
KW - Epithelial ovarian cancer
KW - Gene regulation
KW - Genome-wide association study
KW - eQTL
UR - http://www.scopus.com/inward/record.url?scp=85063043908&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2019.02.023
DO - 10.1016/j.ygyno.2019.02.023
M3 - Article
C2 - 30898391
AN - SCOPUS:85063043908
SN - 0090-8258
VL - 153
SP - 343
EP - 355
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 2
ER -